Key result
Australia adds 5 new cardiovascular drugs versus New Zealand's single addition, highlighting pronounced access disparities.
Why the study?
Publicly subsidised access to new cardiovascular drugs is governed by the PBS in Australia and PHARMAC in New Zealand, but no consolidated resource catalogues recent listings across both jurisdictions.
Recent updates to public drug subsidies reveal significant additions to cardiovascular pharmacotherapy in Australia and a pronounced access disparity between Australia and New Zealand.
Answers are grounded in this paper and cite their sources.
NZ patients face restricted access to novel CV therapies versus Australia; leaves open equity impacts and policy alignment needs.
Background Cardiovascular disease is a leading cause of death in Australia and New Zealand. Publicly subsidised access to new cardiovascular medications is governed by the PBS (Pharmaceutical Benefits Scheme) in Australia and PHARMAC (Pharmaceutical Management Agency) in New Zealand, yet no consolidated resource catalogues recent listings across both jurisdictions. Methods We reviewed all new cardiovascular drug listings and indications on the PBS and PHARMAC schedules from 1 January 2023 to 31 December 2025. PBS data were obtained from the PBS Pricing and Policy Branch through the Cardiac Society for Australia and New Zealand. PHARMAC data were obtained via direct communication with PHARMAC and cross-referenced with public schedule information. Pivotal trial evidence, restriction criteria, and prescribing considerations were extracted from published literature and regulatory documents. Results Five new cardiovascular drugs were PBS-listed (inclisiran, mavacamten, tafamidis, icosapent ethyl and migalastat), two existing drugs received new cardiovascular indications (empagliflozin and dapagliflozin for heart failure with preserved ejection fraction) and prasugrel was relisted for acute coronary syndrome. One major change occurred on the PHARMAC schedule (empagliflozin for heart failure with reduced ejection fraction). Conclusions The 2023–2025 period has seen notable additions to cardiovascular pharmacotherapy in Australia, including the first cardiac myosin inhibitor, the first transthyretin stabiliser, expanded lipid lowering therapy options, and extension of SGLT2 inhibitor coverage across the heart failure ejection fraction spectrum. A pronounced access disparity persists between Australia and New Zealand.
No takes yet. Share an insight, caveat, or question.
Ciofani et al. (2026) conducted a review in Cardiovascular disease. New cardiovascular drug listings was evaluated on New cardiovascular drug listings and indications. Between 2023 and 2025, Australia added five new cardiovascular drugs to the PBS, whereas New Zealand had only one major change on the PHARMAC schedule, highlighting a pronounced access disparity.
Synapse has enriched 10 related papers. Consider them for comparative context: